We are live on ! Find out more
A

Abingworth Portfolio holdings

AUM $307M
1-Year Est. Return 93.47%
This Fund
S&P 500
This Quarter Est. Return
+12.34%
1 Year Est. Return
+93.47%
3 Year Est. Return
+184.38%
5 Year Est. Return
+342.7%
10 Year Est. Return
–
AUM
$112M
AUM Growth
+$1.68M
Cap. Flow
+$1.38M
Cap. Flow %
1.24%
Top 10 Hldgs %
97.03%
Holding
19
New
3
Increased
2
Reduced
2
Closed
5

Top Buys

Rank Stock Value
1
AVDR
Avedro, Inc Common Stock
AVDR
+$9M
2
SIEN
Sientra, Inc.
SIEN
+$2.15M
3
SYRE icon
Spyre Therapeutics
SYRE
+$2.01M
4
RLM
Realm Therapeutics plc American Depositary Shares
RLM
+$716K
5
OCGN icon
Ocugen
OCGN
+$127K

Top Sells

Rank Stock Value
1
OBSV
ObsEva SA Ordinary Shares
OBSV
+$4.54M
2
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$2.72M
3
CLLS
Cellectis
CLLS
+$1.66M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$1.66M
5
ADAP
Adaptimmune Therapeutics
ADAP
+$1.44M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRSP icon
1
CRISPR Therapeutics
CRSP
$4.74B
$41.8M 37.43%
1,171,268
– –
SIEN
2
DELISTED
Sientra, Inc.
SIEN
$20.5M 18.32%
239,084
+19,183
+9% +$2.15M
CHMA
3
DELISTED
Chiasma, Inc. Common Stock
CHMA
$10.7M 9.57%
2,080,595
– –
SLNO
4
DELISTED
Soleno Therapeutics
SLNO
$9.62M 8.61%
311,285
– –
AVDR
5
DELISTED
Avedro, Inc Common Stock
AVDR
$8.73M 7.82%
+719,402
New +$9M
PRTK
6
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$5.59M 5%
1,041,131
– –
VRNA
7
DELISTED
Verona Pharma
VRNA
$5.5M 4.92%
901,943
– –
SRRA
8
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$2.31M 2.06%
34,126
-1,985
-5% -$127K
SYRE icon
9
Spyre Therapeutics
SYRE
$8.92B
$1.93M 1.73%
+9,620
New +$2.01M
CBAY
10
DELISTED
Cymabay Therapeutics
CBAY
$1.74M 1.56%
131,036
– –
OBSV
11
DELISTED
ObsEva SA Ordinary Shares
OBSV
$1.12M 1%
87,999
-352,001
-80% -$4.54M
TARA icon
12
Protara Therapeutics
TARA
$230M
$1.01M 0.9%
50,447
– –
RLM
13
DELISTED
Realm Therapeutics plc American Depositary Shares
RLM
$988K 0.88%
+255,371
New +$716K
OCGN icon
14
Ocugen
OCGN
$440M
$206K 0.18%
29,630
+14,815
+100% +$127K
ADAP
15
DELISTED
Adaptimmune Therapeutics
ADAP
– –
-250,000
Closed -$1.44M
AUPH icon
16
Aurinia Pharmaceuticals
AUPH
$2.01B
– –
-400,434
Closed -$2.72M
CLLS
17
Cellectis
CLLS
$271M
– –
-100,000
Closed -$1.66M
RARE icon
18
Ultragenyx Pharmaceutical
RARE
$2.82B
– –
-38,100
Closed -$1.66M
IMDZ
19
DELISTED
Immune Design Corp.
IMDZ
– –
-352,300
Closed -$458K

Similar funds

AAM
Arabesque Asset Management London, United Kingdom $296M AUM 15.19% 1-Year Est. Return
EP
Equius Partners Novato, California $324M AUM 8.27% 1-Year Est. Return
LDFR
Lehman & Derafelo Financial Resources Media, Pennsylvania $337M AUM 8.16% 1-Year Est. Return
MPAM
Monarch Partners Asset Management Boston, Massachusetts $339M AUM 2.52% 1-Year Est. Return
MAG
Mass Ave Global New York $342M AUM 20.58% 1-Year Est. Return
CDIA
Capital Directions Investment Advisors Atlanta, Georgia $268M AUM 20.15% 1-Year Est. Return
GTCM
Gyon Technologies Capital Management Denville, New Jersey $267M AUM 11.62% 1-Year Est. Return
ACMV
August Capital Management VII Palo Alto, California $265M AUM 26.86% 1-Year Est. Return

Abingworth's Q1 2019 Portfolio in Review

As of Q1 2019, Abingworth held 19 positions worth $112M, up 1.5% from $110M the previous quarter. Its ten largest holdings account for 97% of the portfolio.

Abingworth's Q1 2019 filing shows 3 new, 2 increased, 2 reduced and 5 closed positions. Its largest new stake was Avedro, Inc Common Stock: 719,402 shares worth $8.73M. The largest sale was ObsEva SA Ordinary Shares, an estimated $4.54M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

  • Abingworth's largest Q1 2019 buy was Avedro, Inc Common Stock: 719,402 shares worth $8.73M.
  • Abingworth added most to Sientra, Inc. in Q1 2019, an estimated $2.15M increase.
  • Abingworth's biggest Q1 2019 reduction was ObsEva SA Ordinary Shares, cutting an estimated $4.54M.
  • Abingworth fully exited Aurinia Pharmaceuticals in Q1 2019, selling an estimated $2.72M.
  • Abingworth's ten largest holdings make up 97% of its $112M portfolio in Q1 2019.
  • Abingworth opened 3 new positions and closed 5 in Q1 2019.
  • Abingworth's portfolio value rose 1.5% quarter-over-quarter to $112M.

Based on Abingworth's 13F filing for Q1 2019, filed 15 May 2019.